QNRX - Quoin Pharmaceuticals Ltd - ADR
IEX Last Trade
0.619
0.023 3.716%
Share volume: 79,296
Last Updated: Fri 30 Aug 2024 08:56:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.60
0.02
3.86%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
3.54%
1 Month
4.35%
3 Months
-10.68%
6 Months
-76.01%
1 Year
-88.78%
2 Year
-99.87%
Key data
Stock price
$0.62
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.48 - $6.76
52 WEEK CHANGE
-$0.89
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Shai Yarkoni
Region: US
Website: http://cellect.co
Employees: 8
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://cellect.co
Employees: 8
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
cellect biotechnology was founded in 2011 with a mission to become a global leader in the next generation of cellular therapies by developing innovative solutions for immune system regeneration. achieving higher selectivity, greater specificity and decreased toxicity, cellect envisions its products becoming an integral and essential part of bone marrow transplantation (bmt), as well as integrated into many aspects of regenerative medicine.
Recent news